Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jun 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of using a probiotic solution in sinus rinses to treat chronic sinusitis, a condition where the sinuses become inflamed and blocked, often causing pain and trouble breathing. Researchers want to find out if these probiotic rinses are more effective than regular saline rinses for patients who have previously had sinus surgery. The trial is currently recruiting participants aged 18 and older who are experiencing a worsening of their sinus symptoms, such as nasal congestion or facial pain.
To be eligible, participants must have had sinus surgery at least a year ago and be willing to follow the study procedures. Those currently on certain medications or who have serious health issues will not be able to join the study. If you decide to participate, you will be asked to complete some questionnaires about your symptoms throughout the trial. This research could help improve treatment options for people suffering from chronic sinusitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and female patients 18 years of age or older.
- • 2. Patients diagnosed with acute exacerbation of CRS, defined by worsening of 1 or more sinonasal symptoms (nasal obstruction/congestion, nasal discharge, facial pain/pressure, reduced sense of smell) and inflammatory and/or infectious changes on sinus endoscopy.
- • 3. Patients that have undergone functional endoscopic sinus surgery \> 12 months prior to enrollment as documented in the patients electronic medical record, with patent sinuses deemed suitable for trial on investigator's discretion.
- • 4. Patients must be willing to follow study related procedures for the duration of the study.
- • 5. Patients must understand the purpose and procedures and be willing to sign the study informed consent document.
- • 6. All adult men and women with active CRS will be considered for participation in this study without regard to race, gender, or socioeconomic status.
- Exclusion Criteria:
- • 1. Patients who are taking topical antibiotic irrigations and are unwilling to stop them.
- • 2. Patients who are unable to complete self-administered questionnaires because of cognitive impairment, language barrier, or severe medical conditions.
- • 3. Patients who have a terminal illness (malignancy), immunocompromised (medication-related immunosuppression, immunodeficiency disorder) or systemic disease (granulomatosis polyangiitis or other autoimmune disease with sinonasal manifestations, cystic fibrosis), or recent head/sinonasal trauma that may predispose to infectious complications.
- • 4. Patients who have severe or emergent complications from CRS or presence of a sinus tumor.
- • 5. Female patients who are pregnant or breastfeeding. The patient will be asked if she is pregnant or has any chance of being pregnant. In either case, the patient will be excluded. Note in our consent form this is also addressed (excerpt below).
- • 6. Patients who are taking oral corticosteroids or who have taken oral antibiotics in the previous 2 weeks or on oral corticosteroids.
- • 7. Patients who have upper respiratory infection-type symptoms at time of enrollment, e.g., fevers/chills, sneezing, runny nose, sore throat, coughing. Patients can be eligible for enrollment once symptoms have fully resolved if all other inclusion/exclusion criteria are met.
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Victoria Lee, MD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials